Dr. Yamamoto's MK-677 claims need serious fact-checking

What did @drjorgeyamamoto actually say?

The video caption, not the transcript, carries the substantive claims here. The creator describes MK-677 (Ibutamoren) as "a ghrelin mimetic that acts as a selective stimulator of the growth hormone receptor," arguing it raises both GH and IGF-1 levels and delivers "metabolic and anabolic benefits without the need for injections." The actual spoken transcript is incoherent, appearing to be a transcription error or heavily corrupted audio, so the caption is what we are evaluating.

To the creator's credit, the framing is more pharmacologically precise than most TikTok peptide content. Calling it a ghrelin mimetic rather than just "a GH booster" shows at least some familiarity with the mechanism. But the phrase "without the need for injections" deserves scrutiny, because it implies a clean risk-free alternative to injectable GH secretagogues, and that framing glosses over some real concerns.

Does the science back this up?

Mostly, yes, on the mechanism. The GH-raising effect is one of the better-documented findings in this class of compounds. The evidence on IGF-1 elevation is real, but the "anabolic benefits" framing requires more nuance than the caption provides.

MK-677 binds the ghrelin receptor (GHSR-1a) and stimulates pulsatile GH secretion from the pituitary, which in turn drives hepatic IGF-1 production. This mechanism is established. Nass et al. (2008, Journal of Clinical Endocrinology and Metabolism) demonstrated that MK-677 increased GH and IGF-1 in older adults over 12 months. Svensson et al. (1998, Journal of Clinical Endocrinology and Metabolism) confirmed acute GH pulse amplification in healthy subjects. So the core pharmacology checks out.

The anabolic claim is trickier. Murphy et al. (1998, Journal of Clinical Endocrinology and Metabolism) found lean body mass increases in elderly subjects, but no significant strength gains and some concerning metabolic side effects including fasting glucose elevation and insulin resistance. That is not the clean "anabolic benefit" picture the caption implies.

What did they get wrong (or right)?

They got the mechanism right. Calling MK-677 a selective ghrelin receptor agonist that stimulates GH secretion is accurate and more precise than most creators manage. Credit where it is due.

What they got wrong, or at least incomplete, is the framing of oral dosing as an uncomplicated advantage. The "without the need for injections" line implies oral MK-677 is a simpler, safer path. But MK-677 carries a documented side effect profile that includes increased appetite, water retention, elevated fasting glucose, and potential exacerbation of insulin resistance. These are not trivial. Clemmons et al. (2000, Journal of Clinical Endocrinology and Metabolism) flagged glucose metabolism concerns even at doses studied for therapeutic use.

The caption also says nothing about the regulatory status of MK-677. It is not FDA-approved for any indication. It is not a supplement. Framing its oral bioavailability as a straightforward benefit without mentioning what it actually is legally and clinically creates a misleading impression for a 90,000-view audience.

What should you actually know?

MK-677 raises GH and IGF-1. That part is real. What is also real: it is an investigational compound, not an approved drug, and the long-term safety data in healthy adults optimizing for body composition is essentially nonexistent. Most clinical trials studied specific populations, such as older adults with GH deficiency or hip fracture patients, not young athletes or longevity enthusiasts.

The appetite stimulation is significant enough that some users report substantial weight gain, which cuts against its use as a lean mass tool for people not in a caloric deficit. The glucose effects matter especially if you have any predisposition to metabolic dysfunction.

If you are considering MK-677 for performance or recovery, the honest conversation requires acknowledging that the "no injections needed" appeal does not make it low-risk. It makes it orally convenient. Those are different things. A telehealth provider who does not explain the full risk profile before discussing this compound is not doing their job.